Evidence before promotion

See what peptide research actually supports.

AminoBrief separates approved uses, human findings, early research, and marketing claims. Every public record shows its sources, limitations, review state, and last update.

Education only. No product sales, personalized protocols, or treatment recommendations.

Claim-level sourcesNo orphan claims
Visible review statePending means pending
Public correctionsNo silent rewrites

A smaller, stronger library

Evidence pages should be inspectable, not merely abundant.

Each claim passport separates regulatory status, human evidence, preclinical findings, marketed-product identity, and uncertainty. The first records are intentionally limited while qualified clinical review is being established.

Read the publishing method

First records

Start with claims that are commonly blurred.

Browse all evidence
Ingredient with approved usesUpdated Sep 16

Semaglutide

Approval belongs to specific drug products, indications, formulations, and labels, not every product sold under the ingredient name.

Inspect the claim passport

Two audiences, one standard

Understand the claim, or inspect it professionally.